Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer

…, C Shimizu, A Hirakawa, K Harano… - International journal of …, 2013 - Springer
Background The long-term outcomes and risk factors of paclitaxel-induced peripheral
neuropathy (PIPN) have not yet been fully elucidated. Methods We identified 219 breast cancer …

Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group

K Harano, A Hirakawa, M Yunokawa… - International journal of …, 2016 - Springer
Background Uterine carcinosarcomas (UCSs) are rare and aggressive tumors. The
prognostic factors are not sufficiently known. Methods We performed a multi-institutional, …

TAS-116 (pimitespib), an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: An open-label, dose-finding …

…, D Kotani, Y Kuboki, H Taniguchi, K Harano… - Clinical Cancer …, 2021 - AACR
Purpose: This is a phase Ib trial of TAS-116, an oral HSP90 inhibitor, plus nivolumab for
colorectal cancer and other solid tumors. Patients and Methods: Enrolled patients received TAS-…

Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0)

…, H Bando, Y Fujimoto, S Fukuoka, K Harano… - Cancer …, 2018 - Wiley Online Library
In Japan, the social (medical) health‐care system is on the way to being developed to advance
personalized medicine through the implementation of cancer genomic medicine, known …

Dry sliding friction and Wear behavior of thermoplastic polyurethane against abrasive paper

…, K Shibata, T Nishi, K Moriyasu, K Harano… - Biotribology, 2020 - Elsevier
Thermoplastic polyurethane (TPU) is attractive as the outer sole of running shoes because
of its excellent mechanical properties and ease of processing. This study investigated the …

[HTML][HTML] Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype

K Harano, Y Wang, B Lim, RS Seitz, SW Morris… - PLoS …, 2018 - journals.plos.org
In patients with triple-negative breast cancer (TNBC), tumor-infiltrating lymphocytes (TILs) are
associated with improved survival. Lehmann et al. identified 4 molecular subtypes of TNBC …

[HTML][HTML] MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer

…, L Sun, RH Alvarez, NT Ueno, TM Fouad, K Harano… - Modern Pathology, 2016 - Elsevier
Inflammatory breast cancer is the most aggressive form of breast cancer. Identifying new
biomarkers to be used as therapeutic targets is in urgent need. Messenger RNA expression …

Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE‐826

…, Y Aoki, H Itamochi, M Takekuma, K Harano… - Cancer …, 2022 - Wiley Online Library
Pembrolizumab plus chemotherapy with or without bevacizumab demonstrated prolonged
progression‐free survival (PFS) and overall survival (OS) versus chemotherapy in patients …

[HTML][HTML] Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and …

K Harano, F Terauchi, N Katsumata, F Takahashi… - Annals of …, 2014 - Elsevier
Background Dose-dense weekly paclitaxel (Taxol) and carboplatin (dd-TC) improved
survival compared with conventional tri-weekly paclitaxel and carboplatin (c-TC) as a first-line …

Changes in triple-negative breast cancer molecular subtypes in patients without pathologic complete response after neoadjuvant systemic chemotherapy

H Masuda, K Harano, S Miura, Y Wang… - JCO Precision …, 2022 - ascopubs.org
PURPOSE Lehmann et al have identified four molecular subtypes of triple-negative breast
cancer (TNBC)—basal-like (BL) 1, BL2, mesenchymal (M), and luminal androgen receptor—…